Deaconess is administering monoclonal antibody treatments and antiviral therapies
to help prevent hospitalization for COVID-19. Some of these medications are FDA approved, and others are under emergency use authorization (EUA).
All COVID treatments are available in very limited quantities nationwide. Our strict criteria for qualifying is based upon reducing hospitalizations from COVID-19, as full hospitals affect all patients who may need care.
Due to the prevalence of the omicron variant in our community, we are administering sotrovimab, as it is the only monoclonal antibody treatment effective against this variant. This medication is given as an infusion treatment of mild-to-moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization.
This oral medication is available by prescription only, is filled through the Deaconess Family Pharmacy Gateway, and only after a DC live visit and a thorough review of potentially dangerous interacting medications by a Deaconess pharmacist.
This FDA-approved medication is given as an infusion treatment of mild-to-moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization.
This oral medication is available by prescription only, and is only available through certain retail pharmacies (not Deaconess).
Due to extremely limited quantities, below are the criteria for these outpatient treatments:
Patients must have had symptoms for less than 5-7 days.
These treatments are NOT authorized for:
All moderately-to-severely immunocompromised patients regardless of vaccination status (adult and pediatric)
Patients age 65 and older
Unvaccinated patients age 55-64 with at least one risk factor below
Qualifying risk factors:
- BMI ≥ 35
- Chronic Kidney Disease
- Cardiovascular disease
- COPD/chronic respiratory disease
Unvaccinated pregnant patients
Vaccinated pregnant patients who are at least 24 weeks gestational age
Unvaccinated with Trisomy 21/Down syndrome or intellectual disability that requires group home status
Unvaccinated with cerebral palsy
Age < 18, unvaccinated with one of the following:
Trisomy 21/Down syndrome or intellectual disability that requires group home status
Type 1 Diabetes Mellitus
BMI in the 95th percentile for age
Sickle Cell disease (not trait)
Treatment should be started as early as possible.
- Patients who are already seriously ill due to COVID-19 (already hospitalized, on oxygen)
- Patients with COVID-19 symptom onset > 5-7 days
- Clinical trial data shows most benefit in patients with symptoms of 5-7 days or less, depending on which treatment is available.
If you believe you are a candidate for one of these treatments, schedule an appointment now with a Deaconess Clinic LIVE
provider. They will assess your symptoms and/or risks, and will schedule any needed appointments for treatment.
Some of these treatments will have out-of-pocket costs
for the medication itself, or costs to administer the medication, or both. To learn what your costs may be based on your specific insurance, call 812-450-COST (2678).
*Maryland Department of Health. What are Monoclonal Antibodies Infographic, Retrieved 2021, Aug 20, from https://health.maryland.gov/preparedness/Pages/Monoclonal-Antibodies-Treatment-for-COVID-19.aspx